New enterovirus 71 vaccine with 99.21% effectiveness to be mass-produced in 2025
New enterovirus 71 vaccine with 99.21% effectiveness to be mass-produced in 2025
2024-07-02
Every year between May and June enterovirus infections reach their peak. This extremely contagious virus puts fear in the hearts of parents with children aged 5 and below, a high-risk group for complications. On Tuesday, a subsidiary of vaccine manufacturing giant Adimmune provided some good news: its new EV-71 vaccine with a 99.21% effectiveness rate will hit the market in 2025.
Adimmune subsidiary Enimmune held a press conference on Tuesday to announce the unblinded results of its Phase III clinical trials for a vaccine against enterovirus 71.
Vic Chang
Enimmune
Around the world we’ve done clinical trials in many countries and many different medical centers. Now the main topic for today is about the unblinded results of our clinical trial. So the effectiveness reached 99.21%, making it extremely effective. As for the protection it provides, it’s more effective than all the products that are currently for sale on the market.
Enterovirus is a contagious virus that often infects children. Infections peak in May or June every year, and the virus spreads by fecal–oral transmission and airborne transmission. Most people who are infected have symptoms like a mild fever or mouth ulcers. EV-71 is considered the most dangerous enterovirus, as it has a high mortality rate. In the past, the most effective vaccine on the market was Medigen’s, with an effectiveness of 96.8%.
Vic Chang
President of Enimmune
We’ll still be taking our vaccine to many countries that’ll need it, which includes countries in Southeast Asia, China and countries in Northeast Asia, an area that’s currently in the middle of an enterovirus epidemic period. As for the quantity for Taiwan, starting from right now we’ll have a smaller amount available, but next year we’ll substantially increase the numbers.
Enimmune currently has about 50,000 doses of the EV-71 vaccine, but by next year it’ll mass-produce the vaccine so that over 100,000 doses will be available. Anticipating that in 2026 it’ll receive medical approval from Vietnam, the subsidiary pharma company has its sights set on the newborn market in countries throughout Southeast Asia.
For more Taiwan news, tune in:
Sun to Fri at 9:30 pm on Channel 152
Tue to Sat at 1 am on Channel 53
腸病毒71型疫苗三期解盲達標 安特羅拚明年量產
2024-07-02
腸病毒傳染力強，每年5到6月是高峰期，尤其5歲以下嬰幼兒更是重症高危險群，讓不少家長心驚驚，今天國光生技旗下子公司「安特羅」宣布、「腸病毒71型疫苗第三期」臨床試驗解盲達標，保護力高達99.21%，預估明年將擴大量產，目標產出10萬劑以上。
國光生技旗下子公司「安特羅」召開記者會，宣布’’腸病毒71型疫苗第三期’’臨床試驗解盲達標。
[[安特羅總經理 張哲瑋]]
“我們在整個全球裡面，做了多國多中心的臨床試驗，那麼今天主要是，針對療效試驗的部分做了一個解盲，所以我們保護力來到了99.21%，那證明說這個疫苗，是非常非常有效的，而且這個保護力，也是在所有現在，目前的市售產品當中，最高保護力的”
腸病毒是常見的兒童傳染病，每年5月、6月為高峰期，可透過糞口或飛沫等傳播途徑，多數患者輕微發燒、口腔潰瘍，其中腸病毒71型併發症最嚴重，死亡風險高，之前市面上只有高端疫苗，保護力96.8%。
[[安特羅總經理 張哲瑋]]
我們還會進軍到，很多需要的國家，包含東南亞、中國，包含東北亞現在，目前都在流行了，那麼台灣的量，我們會從現在初期的比較少的量，明年會整個大幅的擴增”
目前安特羅生產的腸病毒71型疫苗，約為5萬劑，明年將擴大量產，可超過10萬劑以上，也預定2026年要拼取越南藥證，鎖定東南亞各國新生兒市場。
更多新聞內容，請鎖定：
民視台灣台（152頻道）週日至週五晚上9:30
民視新聞台（53頻道）週二至週六凌晨1:00
Related News
